期刊文献+

Shorter recurrence-free survival time, higher risk of multiple recurrences: a retrospective study of non-muscle invasive bladder cancer after transurethral resection 被引量:2

Shorter recurrence-free survival time, higher risk of multiple recurrences: a retrospective study of non-muscle invasive bladder cancer after transurethral resection
原文传递
导出
摘要 Background Multiple recurrences are common in non-muscle invasive bladder cancer, but the-risk of multiple recurrences has not been fully described. Identifying patients at high risk of multiple recurrences will help to select an optimal therapeutic strategy and to improve prognosis. This study was conducted to identify the risk factors for multiple recurrences of non-muscle invasive bladder cancer. Methods We reviewed the clinical data of all patients with non-muscle invasive bladder cancer in our hospital between January 2003 and February 2010. Patients with at least one recurrence were included. Multivariate analysis was performed for theorized risk factors (age, gender, tumor stage, grade, size, location, number of lesions, adjuvant intra-vesical chemotherapy after transurethral resection, and recurrence-free survival after each resection) to clarify risk factors for multiple recurrences of non-muscle invasive bladder cancer. Results Of the 278 patients with non-muscle invasive bladder cancer, 84 were with at least one recurrence and a total of 222 recurrences among them were followed up for 6-70 months (mean, 36.1 months). Recurrence-free survival after initial resection predicted the overall frequency of bladder cancer recurrence (risk ratio (RR) = 37.83, 95% confidence interval (C/)=3.45-396.13, P=0.001) and second recurrence (RR=6.15, 95% C/=1.28-29.57, P=0.023). Similarly, recurrence-free survival after a second resection was the only significant risk factor for third recurrence (RR=31.08, 95% C1=2.53-381.47, P=0.007). Moreover, recurrence-free survival after initial resection was the only significant factor to predict later progression to muscle invasive bladder cancer (RR=8.62, 95% C1=1.47-58.34, P=0.001). Conclusions Recurrence-free survival after resection is an independent predictor of multiple recurrences of non-muscle invasive bladder cancer. The shorter the period between resection and recurrence is, the higher the risk of multiple recurrences. Background Multiple recurrences are common in non-muscle invasive bladder cancer, but the-risk of multiple recurrences has not been fully described. Identifying patients at high risk of multiple recurrences will help to select an optimal therapeutic strategy and to improve prognosis. This study was conducted to identify the risk factors for multiple recurrences of non-muscle invasive bladder cancer. Methods We reviewed the clinical data of all patients with non-muscle invasive bladder cancer in our hospital between January 2003 and February 2010. Patients with at least one recurrence were included. Multivariate analysis was performed for theorized risk factors (age, gender, tumor stage, grade, size, location, number of lesions, adjuvant intra-vesical chemotherapy after transurethral resection, and recurrence-free survival after each resection) to clarify risk factors for multiple recurrences of non-muscle invasive bladder cancer. Results Of the 278 patients with non-muscle invasive bladder cancer, 84 were with at least one recurrence and a total of 222 recurrences among them were followed up for 6-70 months (mean, 36.1 months). Recurrence-free survival after initial resection predicted the overall frequency of bladder cancer recurrence (risk ratio (RR) = 37.83, 95% confidence interval (C/)=3.45-396.13, P=0.001) and second recurrence (RR=6.15, 95% C/=1.28-29.57, P=0.023). Similarly, recurrence-free survival after a second resection was the only significant risk factor for third recurrence (RR=31.08, 95% C1=2.53-381.47, P=0.007). Moreover, recurrence-free survival after initial resection was the only significant factor to predict later progression to muscle invasive bladder cancer (RR=8.62, 95% C1=1.47-58.34, P=0.001). Conclusions Recurrence-free survival after resection is an independent predictor of multiple recurrences of non-muscle invasive bladder cancer. The shorter the period between resection and recurrence is, the higher the risk of multiple recurrences.
机构地区 Department of Urology
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第20期3681-3686,共6页 中华医学杂志(英文版)
关键词 bladder cancer recurrence risk factors recurrence-free survival bladder cancer," recurrence," risk factors recurrence-free survival
  • 相关文献

参考文献1

二级参考文献10

  • 1Chung M,Steinmetz OK,Gordon PH.Preoperative blood transfusion and outcome after resection for colorectal carcinoma[].British Journal of Surgery.1993
  • 2Narayana AS,,Loening SA,Slymen DJ,Culp DA.Bladder cancer: factors affecting survival[].Journal d Urologie.1983
  • 3Flamm J,Havelec L.Factors affecting survival in primary superficial bladder cancer[].European Urology.1990
  • 4Kiemeney LA,Witjes JA,Heijbroek RP,Verbeek AL,Debruyne FM.Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer[].Journal d Urologie.1993
  • 5Loening S,Narayana A,Yoder L,Slymen D,Penick G,Culp D.Analysis of bladder tumor recurrence in 178 patients[].Urology.1980
  • 6Thrasher JB,Crawford ED.Current management of invasive and metastatic transitional cell carcinoma of the bladder[].Journal d Urologie.1993
  • 7Shinka T,Matsumoto M,Ogura H,Hirano A,Ohkawa T.Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guerin: a long-term follow-up[].International Journal of Urology.1997
  • 8Rodriguez-Alonso A,Pita-Fernandez S,Gonzalez-Carrero J,Nogueira-March JL.Multivariate analysis of survival, recurrence, progression and development of mestastasis in T1 and T2a transitional cell bladder carcinoma[].Cancer.2002
  • 9Heney NM,Ahmed S,Flanagan MJ,Frable W,Corder MP,Hafermann MD, et al.Superficial bladder cancerProgression and recurrence[].J Urol.1983
  • 10Herr HW,,Badalament RA,Amato DA,Laudone VP,Fair WR,Whitmore WF Jr.Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression[].Journal d Urologie.1989

共引文献2

同被引文献22

  • 1Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer:epidemiol- ogy, staging and grading, and diagnosis[J]. Urology, 2005, 66 (Suppl 6A) :4-34.
  • 2Zhu Y, Jiang X, Zhang J, et al. Safety and efficacy of holmium la- ser resection for primary nonmuscle-invasive bladder cancer versus transurethral electroresection: single-center experience[J]. Urolo gy, 2008,72(3) : 608 - 612.
  • 3Marko B. Transurethral Resection of Non-muscle-invasive Blad- der Cancer[J]. Eur Urol,2009,8(7):542-548.
  • 4Zhong C, Guo S, Tang Y,et al. Clinical observation on 2 micron la ser for non-muscle invasivebiadder tumor treatment single center experience[J]. World J Urol,2010,28(2) : 157-161.
  • 5Van S den I3osch S, Al{red Witjes J. Long-term Cancer specific Survival in Patients with High- risk, Non- muscle- invasive Blad der Cancer and Turnout Progression: A Systematic Review[J]. Eur Urol, 2011, 60(3) :493-500.
  • 6Mario W K, Thorsten B, Mathias W, et al. Current evidence for transurethral laser therapy of non-muscle invasive bladder cancer [J]. World J Urol,2011,29(4) :433-442.
  • 7Eichler J,Goncalves (7). A Review of Different I.asers in Endonasal Surgery: Ar-, KTP-, Dye , Diode , N&, Ho- and COz-Laser[J 7. Med Laser Appl, 2002,17(3) : 190-200.
  • 8戴奇山,钟惟德,毕学成,韩兆冬,何朝辉,何永忠,李逊,张阳德.大功率绿激光光选择汽化术治疗前列腺增生症(附72例报告)[J].中国内镜杂志,2010,16(2):187-189. 被引量:5
  • 9曹时益,曹智修.绿激光汽化术和电切术治疗浅表性膀胱癌的比较[J].医学与哲学(B),2011,32(2):48-49. 被引量:8
  • 10张栋,金讯波,孙鹏,李鹏,尉春晓,袁航,张琦.膀胱尿道软镜联合绿激光治疗前列腺增生术后后尿道狭窄与闭锁[J].山东大学学报(医学版),2011,49(7):129-131. 被引量:6

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部